Ftse Mib
34.603,61
-0,64%
DAX
18.726,76
-0,21%
S&P 500
5.321,41
0,25%
NASDAQ
16.832,62
0,22%
Bitcoin
69.847,58
-0,40%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Axovant Gene Therapies Ltd (AXGT) Axovant Gene Therapies Ltd (AXGT) Notizie

AXGT

Axovant Gene Therapies (AXGT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AXGT
DataOraFonteTitoloSimboloCompagnia
25/04/202322:05Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:AXGTAxovant Gene Therapies Ltd
17/04/202322:17Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:AXGTAxovant Gene Therapies Ltd
17/04/202322:14Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AXGTAxovant Gene Therapies Ltd
12/04/202314:52Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/04/202322:08Edgar (US Regulatory)Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/04/202322:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
17/03/202311:03Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
21/02/202322:06Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
14/02/202312:47Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AXGTAxovant Gene Therapies Ltd
13/02/202314:53Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/02/202322:01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:AXGTAxovant Gene Therapies Ltd
09/02/202312:01Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
14/06/202213:02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/02/202223:08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/10/202123:19Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/08/202122:15Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
16/12/202013:00Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:AXGTAxovant Gene Therapies Ltd
02/12/202013:00GlobeNewswire Inc.Sio Gene Therapies Announces First Patient Dosed in High-Dose Cohort of AXO-AAV-GM1 Clinical Trial in Patients with GM1 Gangl...NASDAQ:AXGTAxovant Gene Therapies Ltd
20/11/202012:04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AXGTAxovant Gene Therapies Ltd
19/11/202014:00GlobeNewswire Inc.Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific AdvisorNASDAQ:AXGTAxovant Gene Therapies Ltd
13/11/202013:06Edgar (US Regulatory)Registration of Securities of Successor Issuers (8-k12g3)NASDAQ:AXGTAxovant Gene Therapies Ltd
13/11/202013:00GlobeNewswire Inc.Sio Gene Therapies Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2020NASDAQ:AXGTAxovant Gene Therapies Ltd
10/11/202023:11Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/11/202013:00GlobeNewswire Inc.Axovant Gene Therapies Announces Name Change to Sio Gene TherapiesNASDAQ:AXGTAxovant Gene Therapies Ltd
09/11/202013:00GlobeNewswire Inc.Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff DiseasesNASDAQ:AXGTAxovant Gene Therapies Ltd
29/10/202021:01GlobeNewswire Inc.Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D Day on October 30, 202...NASDAQ:AXGTAxovant Gene Therapies Ltd
22/10/202013:00GlobeNewswire Inc.Axovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on October 30, 2020NASDAQ:AXGTAxovant Gene Therapies Ltd
13/10/202013:00GlobeNewswire Inc.Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff DiseaseNASDAQ:AXGTAxovant Gene Therapies Ltd
09/10/202013:00GlobeNewswire Inc.Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 GangliosidosisNASDAQ:AXGTAxovant Gene Therapies Ltd
08/10/202013:00GlobeNewswire Inc.Axovant Gene Therapies Strengthens Board of Directors and Announces New Chief Commercial OfficerNASDAQ:AXGTAxovant Gene Therapies Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AXGT

La tua Cronologia

SUSHI
ELXETH
Energy Ledger
ASX
IDAND
Indiana Resources
XE
DFV
DFV Deutsche Familienver...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network